Product Pipeline

Pulmonary Hypertension

Pulmonary Arterial Hypertension (PAH) is a debilitating disease with a poor prognosis and limited therapeutic options. PAH affects approximately 200,000 worldwide making it eligible for orphan drug designation. Current therapies for PAH, such at PDE-5 inhibitors, target single endothelial-based pathways and fail to significantly reduce mortality in patients.

Based on preclinical studies conducted by Sagene, selegiline combined with PDE-5 inhibitors will enhance existing efficacy at lower doses by decreasing platelet activation and increasing levels of NO (nitric oxide), thus preventing the progression of PAH.